Structure Therapeutics In... (GPCR)
Structure Therapeutics Statistics
Share Statistics
Structure Therapeutics has 19.1M shares outstanding. The number of shares has increased by 0.42% in one year.
| Shares Outstanding | 19.1M |
| Shares Change (YoY) | 0.42% |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | 38.37% |
| Shares Floating | 18.16M |
| Failed to Deliver (FTD) Shares | 201 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -43.01 and the forward PE ratio is -12.66. Structure Therapeutics's PEG ratio is -8.6.
| PE Ratio | -43.01 |
| Forward PE | -12.66 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | 6.09 |
| P/FCF Ratio | -44.68 |
| PEG Ratio | -8.6 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Structure Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.74, with a Debt / Equity ratio of 0.
| Current Ratio | 24.74 |
| Quick Ratio | 24.74 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-751.69K |
| Employee Count | 163 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 310K |
| Effective Tax Rate | -0.25% |
Stock Price Statistics
The stock price has increased by -31.54% in the last 52 weeks. The beta is -1.46, so Structure Therapeutics's price volatility has been lower than the market average.
| Beta | -1.46 |
| 52-Week Price Change | -31.54% |
| 50-Day Moving Average | 20.68 |
| 200-Day Moving Average | 31.33 |
| Relative Strength Index (RSI) | 73.82 |
| Average Volume (20 Days) | 954.61K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -158.23M |
| Net Income | -122.53M |
| EBITDA | -158.23M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.63 |
Balance Sheet
The company has 169.51M in cash and 3.86M in debt, giving a net cash position of 165.65M.
| Cash & Cash Equivalents | 169.51M |
| Total Debt | 3.86M |
| Net Cash | 165.65M |
| Retained Earnings | -329.1M |
| Total Assets | 903.33M |
| Working Capital | 855.19M |
Cash Flow
In the last 12 months, operating cash flow was -116.64M and capital expenditures -1.29M, giving a free cash flow of -117.93M.
| Operating Cash Flow | -116.64M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -117.93M |
| FCF Per Share | -0.2 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GPCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for GPCR is $83.5, which is 210.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $83.5 |
| Price Target Difference | 210.2% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 7.11 |
| Piotroski F-Score | 2 |